Research priorities for expanding access to methadone treatment for opioid use disorder in the United States: A National Institute on Drug Abuse Center for Clinical Trials Network Task Force report.

dc.contributor.author

Joudrey, Paul J

dc.contributor.author

Bart, Gavin

dc.contributor.author

Brooner, Robert K

dc.contributor.author

Brown, Lawrence

dc.contributor.author

Dickson-Gomez, Julie

dc.contributor.author

Gordon, Adam

dc.contributor.author

Kawasaki, Sarah S

dc.contributor.author

Liebschutz, Jane M

dc.contributor.author

Nunes, Edward

dc.contributor.author

McCarty, Dennis

dc.contributor.author

Schwartz, Robert P

dc.contributor.author

Szapocnik, José

dc.contributor.author

Trivedi, Madhukar

dc.contributor.author

Tsui, Judith I

dc.contributor.author

Williams, Arthur

dc.contributor.author

Wu, Li-Tzy

dc.contributor.author

Fiellin, David A

dc.date.accessioned

2021-11-01T20:41:36Z

dc.date.available

2021-11-01T20:41:36Z

dc.date.issued

2021-01

dc.date.updated

2021-11-01T20:41:35Z

dc.description.abstract

In the US, methadone treatment can only be provided to patients with opioid use disorder (OUD) through federal and state-regulated opioid treatment programs (OTPs). There is a shortage of OTPs, and racial and geographic inequities exist in access to methadone treatment. The National Institute on Drug Abuse Center for Clinical Trials Network convened the Methadone Access Research Task Force to develop a research agenda to expand and create more equitable access to methadone treatment for OUD. This research agenda included mechanisms that are available within and outside the current regulations. The task force identified 6 areas where research is needed: (1) access to methadone in general medical and other outpatient settings; (2) the impact of methadone treatment setting on patient outcomes; (3) impact of treatment structure on outcomes in patients receiving methadone; (4) comparative effectiveness of different medications to treat OUD; (5) optimal educational and support structure for provision of methadone by medical providers; and (6) benefits and harms of expanded methadone access. In addition to outlining these research priorities, the task force identified important cross-cutting issues, including the impact of patient characteristics, treatment, and treatment system characteristics such as methadone formulation and dose, concurrent behavioral treatment, frequency of dispensing, urine or oral fluid testing, and methods of measuring clinical outcomes. Together, the research priorities and cross-cutting issues represent a compelling research agenda to expand access to methadone in the US.

dc.identifier.issn

0889-7077

dc.identifier.issn

1547-0164

dc.identifier.uri

https://hdl.handle.net/10161/23959

dc.language

eng

dc.publisher

Informa UK Limited

dc.relation.ispartof

Substance abuse

dc.relation.isversionof

10.1080/08897077.2021.1975344

dc.subject

Access

dc.subject

methadone

dc.subject

opioid use disorder

dc.title

Research priorities for expanding access to methadone treatment for opioid use disorder in the United States: A National Institute on Drug Abuse Center for Clinical Trials Network Task Force report.

dc.type

Journal article

duke.contributor.orcid

Wu, Li-Tzy|0000-0002-5909-2259

pubs.begin-page

245

pubs.end-page

254

pubs.issue

3

pubs.organisational-group

School of Medicine

pubs.organisational-group

Center for Child and Family Policy

pubs.organisational-group

Duke Institute for Brain Sciences

pubs.organisational-group

Medicine, General Internal Medicine

pubs.organisational-group

Duke

pubs.organisational-group

Sanford School of Public Policy

pubs.organisational-group

University Institutes and Centers

pubs.organisational-group

Institutes and Provost's Academic Units

pubs.organisational-group

Medicine

pubs.organisational-group

Clinical Science Departments

pubs.publication-status

Published

pubs.volume

42

Files